Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Tyrosine kinase receptor expression in thymomas

Tyrosine kinase receptor expression in thymomas J Cancer Res Clin Oncol (2004) 130: 222–224 DOI 10.1007/s00432-004-0545-z ORIGINAL PAPER John D. Henley Æ Oscar W. Cummings Patrick J. Loehrer, Sr. Received: 9 December 2003 / Accepted: 24 December 2003 / Published online: 5 February 2004 Springer-Verlag 2004 Abstract Purpose: Promising new therapies for neopla- Introduction sia include tyrosine kinase receptor antagonists. Tyro- sine kinase oncogenes present an appealing anti-tumor Recent advances (Bonner et al. 2000, Hoffmann et al. drug target since they play an integral role in a variety of 1997, Kelloff et al. 1993, Rubin et al. 2000, Yang et al. cellular responses including cell proliferation and dif- 2000, 1999] using tyrosine kinase antagonists in the ferentiation. We previously demonstrated a high rate of treatment of neoplasia have stimulated our interest in epidermal growth factor receptor (EGFR) expression in expression of these molecules in epithelial tumors of the advanced-stage thymic epithelial tumors. More recently, thymus. Tyrosine kinase oncogenes present an appealing we have examined c-KIT (CD117) expression in a sim- anti-tumor drug target since they play an integral role in ilar series of tumors. Methods: Tumor from 35 patients a variety of cellular responses including cell prolifera- seen at our institution for treatment of advanced-stage http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cancer Research and Clinical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/tyrosine-kinase-receptor-expression-in-thymomas-rP908mvbSm

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2004 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Cancer Research; Internal Medicine; Hematology
ISSN
0171-5216
eISSN
1432-1335
DOI
10.1007/s00432-004-0545-z
pmid
14762710
Publisher site
See Article on Publisher Site

Abstract

J Cancer Res Clin Oncol (2004) 130: 222–224 DOI 10.1007/s00432-004-0545-z ORIGINAL PAPER John D. Henley Æ Oscar W. Cummings Patrick J. Loehrer, Sr. Received: 9 December 2003 / Accepted: 24 December 2003 / Published online: 5 February 2004 Springer-Verlag 2004 Abstract Purpose: Promising new therapies for neopla- Introduction sia include tyrosine kinase receptor antagonists. Tyro- sine kinase oncogenes present an appealing anti-tumor Recent advances (Bonner et al. 2000, Hoffmann et al. drug target since they play an integral role in a variety of 1997, Kelloff et al. 1993, Rubin et al. 2000, Yang et al. cellular responses including cell proliferation and dif- 2000, 1999] using tyrosine kinase antagonists in the ferentiation. We previously demonstrated a high rate of treatment of neoplasia have stimulated our interest in epidermal growth factor receptor (EGFR) expression in expression of these molecules in epithelial tumors of the advanced-stage thymic epithelial tumors. More recently, thymus. Tyrosine kinase oncogenes present an appealing we have examined c-KIT (CD117) expression in a sim- anti-tumor drug target since they play an integral role in ilar series of tumors. Methods: Tumor from 35 patients a variety of cellular responses including cell prolifera- seen at our institution for treatment of advanced-stage

Journal

Journal of Cancer Research and Clinical OncologySpringer Journals

Published: Feb 5, 2004

There are no references for this article.